Phase II Study of CDK 4/6 Inhibitor, LEE011 (Ribociclib), in Combination With Adjuvant Endocrine Therapy at Varying Duration for ER-positive Breast Cancer (LEADER)
Latest Information Update: 03 Apr 2024
At a glance
- Drugs Ribociclib (Primary) ; Aromatase inhibitors
- Indications Advanced breast cancer; Early breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms LEADER
- 06 Dec 2023 According to a Natera media release, data from this study are being presented at the 2023 San Antonio Breast Cancer Symposium (SABCS).
- 07 Dec 2022 According to a Natera media release, new clinical data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, and its hereditary cancer test, Empower, will be presented at the 2022 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas.
- 25 Oct 2021 Planned End Date changed from 1 Oct 2024 to 1 Oct 2026.